欢迎来到天天文库
浏览记录
ID:53736023
大小:222.91 KB
页数:3页
时间:2020-04-21
《重组人p53腺病毒注射液联合顺铂胸腹腔内注射治疗恶性胸腹水疗效观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、48武警医学2014年1月第25卷第1期MedJChinPAPF,Vo1.25,No.1,Janua~.2014重组人p53腺病毒注射液联合顺铂胸腹腔内注射治疗恶性胸腹水疗效观察赵凤翎,罗社文,毛积分,宋晓萍,刘明贺,许莉【摘要】目的观察胸腹腔内注射重组人p53腺病毒注射液联合顺铂治疗恶性胸腹水的疗效。方法选择住院治疗的42例恶性朐腹水患者,随机分为两组,每组21例。观察组先将胸腹水经穿刺放液尽量引流后,胸腔内灌注重组人p53腺病毒注射液2×10VP,腹腔内灌注重组人p53腺病毒注射液4x10”VP,灌注后帮助患者改变体位,24h后再注入顺铂40rag/in
2、,每周重复1次,4次为一疗程。对照组只应用顺铂。观察患者接受治疗后的临床症状评分、生活质量、卡氏评分及不良反应等的变化,同时记录生存期。结果观察组疾病控制率(CR+PR+sD)为85.7%(18/21),对照组为57.1%(12/21)(P<0.05)。观察组生存质量卡氏评分提高率为76.2%(16/21),对照组为38.1%(8/21)(P<0.05)。结论胸腹腔内注射重组人p53腺病毒注射液联合顺铂治疗恶性胸腹水的临床疗效好,具有重要的临床价值,不良反应轻微。【关键词】重组人p53腺病毒注射液;恶性胸腹腔积液;基因治疗【中国图书分类号】R57Clinic
3、alstudyofcombinedapplicationofrecombinanthumanadenovirusp53injectedintothoraciccavityandabdominalcavitywithcisplatintherapyintreatingmalignantthoraciccavityandabdomencavityefusionZHAOFengling,LUOShewen,MAOJifen,SONGXiaoping,LIUMinghe,andXULi·FirstCadresDepartment,GeneralHospi—talof
4、ChinesePeople’sArmedPoliceForces,Beijing100039,China【Abstract】ObjectiveToevaluatetheclinicalvalueofcombinedapplicationofrecombinanthumanadenovirusp53injectedintothoraciccavityandabdominalcavitywithcisplatintherapyintreatingmalignantthoraciccavityandabdomencavityeffusion.MethodsFort
5、y—twopatientswithmalignantthoracicorabdomencavityeffusioninthishospitalfromJanurary2010toDecember2012wereincludedinthisstudy.Thepatientsweredividedintotwogroups:forobservationgroup(=21),recombinant2×10VPhu—nlanadenovirusp53injectedintothoraciccavity.recombinant4×10VPhumanadenovirus
6、p53injectedintoabdominalcavityafteroutfloweffusionbypuncture.Patientsweredemandedtochangetheirpositionafterinjection,40mg/mcisplatininjectionwasper—formedafter24hours.Theinjectionwasrepeatedonceeveryweekand4timeswasatherapyperiod.Forcontrolgroup(n=21),onlycisplatinwasused.Theclinic
7、algrading,qualityoflife,Kashigrading,anduntowardreactionswereobservedandrecordedforallpa—tients.Survivalperiodwasrecordedatthesametime.ResultsTheeficiencyrateoftherapy(CR+PR+SD)forobservationgroupwas85.7%(18/21),whilethatforcontrolgroupwas57.1%(12/21)(P<0.05).TheincreaseinKashigrad
8、ingoflivingqualitywas76.2%
此文档下载收益归作者所有